Crystal Structure of Refolding Fusion Core of Lassa Virus GP2 and Design of Lassa Virus Fusion Inhibitors

The envelope glycoproteins GP1 and GP2 of Lassa virus (LASV) bind to the host cell receptors to mediate viral infection. So far, no approved vaccines and specific treatment options against LASV exist. To develop specific fusion inhibitors against LASV, we solved the crystal structure of the post-fusion 6 helix bundle (6-HB) formed by two heptad repeat domains (HR1 and HR2) of GP2. This fusion core contains a parallel trimeric coiled-coil of three HR1 helices, around which three HR2 helices are entwined in an antiparallel manner. Various hydrophobic and charged interactions form between HR1 and HR2 domains to stabilize the overall conformation of GP2 fusion core. Based on the structure, we designed several peptides spanning the HR2 domain and tested their antiviral activities. We found that the longer HR2 peptides were effective in inhibiting LASV GPC protein-mediated cell–cell fusion under low pH condition. These results not only suggest that LASV infects the target cell mainly through endocytosis, including micropinocytosis, and membrane fusion at low pH, but also provide an important basis for rational design of LASV fusion inhibitors.

[1]  Y. Levy,et al.  Variations in Core Packing of GP2 from Old World Mammarenaviruses in their Post-Fusion Conformations Affect Membrane-Fusion Efficiencies. , 2019, Journal of molecular biology.

[2]  Lu Lu,et al.  A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike , 2019, Science Advances.

[3]  Shibo Jiang,et al.  Discovery of Hydrocarbon-Stapled Short α-Helical Peptides as Promising Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Fusion Inhibitors , 2018, Journal of medicinal chemistry.

[4]  Lu Lu,et al.  Peptide-Based Membrane Fusion Inhibitors Targeting HCoV-229E Spike Protein HR1 and HR2 Domains , 2018, International journal of molecular sciences.

[5]  Lu Lu,et al.  Development of small-molecule viral inhibitors targeting various stages of the life cycle of emerging and re-emerging viruses , 2017, Frontiers of Medicine.

[6]  M. Wang,et al.  An LASV GPC pseudotyped virus based reporter system enables evaluation of vaccines in mice under non-BSL-4 conditions. , 2017, Vaccine.

[7]  K. Chandran,et al.  Structural basis for antibody-mediated neutralization of Lassa virus , 2017, Science.

[8]  Lu Lu,et al.  A novel HIV-1 gp41 tripartite model for rational design of HIV-1 fusion inhibitors with improved antiviral activity , 2017, AIDS.

[9]  D. Dimitrov,et al.  HIV-1 gp41-targeting fusion inhibitory peptides enhance the gp120-targeting protein-mediated inactivation of HIV-1 virions , 2017, Emerging Microbes &Infections.

[10]  Rongguang Zhang,et al.  Rational improvement of gp41-targeting HIV-1 fusion inhibitors: an innovatively designed Ile-Asp-Leu tail with alternative conformations , 2016, Scientific Reports.

[11]  G. Torriani,et al.  Lassa Virus Cell Entry via Dystroglycan Involves an Unusual Pathway of Macropinocytosis , 2016, Journal of Virology.

[12]  Thomas Strecker,et al.  Acidic pH-Induced Conformations and LAMP1 Binding of the Lassa Virus Glycoprotein Spike , 2016, PLoS pathogens.

[13]  Q. Wang,et al.  Improved Pharmacological and Structural Properties of HIV Fusion Inhibitor AP3 over Enfuvirtide: Highlighting Advantages of Artificial Peptide Strategy , 2015, Scientific Reports.

[14]  Lu Lu,et al.  Protective Effect of Intranasal Regimens Containing Peptidic Middle East Respiratory Syndrome Coronavirus Fusion Inhibitor Against MERS-CoV Infection , 2015, The Journal of infectious diseases.

[15]  Pardis C Sabeti,et al.  Lassa Fever in Post-Conflict Sierra Leone , 2014, PLoS neglected tropical diseases.

[16]  Lu Lu,et al.  Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor , 2014, Nature Communications.

[17]  H. Feldmann,et al.  Lassa Fever in West Africa: Evidence for an Expanded Region of Endemicity , 2012, Zoonoses and public health.

[18]  Pardis C Sabeti,et al.  Molecular Diagnostics for Lassa Fever at Irrua Specialist Teaching Hospital, Nigeria: Lessons Learnt from Two Years of Laboratory Operation , 2012, PLoS neglected tropical diseases.

[19]  K. Chandran,et al.  Inhibition of Ebola Virus Entry by a C-peptide Targeted to Endosomes , 2011, The Journal of Biological Chemistry.

[20]  N. Tordo,et al.  Characterization of Lassa Virus Cell Entry and Neutralization with Lassa Virus Pseudoparticles , 2009, Journal of Virology.

[21]  Randy J Read,et al.  Automated structure solution with the PHENIX suite. , 2008, Methods in molecular biology.

[22]  S. Kunz,et al.  Different Mechanisms of Cell Entry by Human-Pathogenic Old World and New World Arenaviruses , 2008, Journal of Virology.

[23]  R. Davey,et al.  Arenavirus entry occurs through a cholesterol-dependent, non-caveolar, clathrin-mediated endocytic mechanism. , 2007, Virology.

[24]  Airlie J. McCoy,et al.  Solving structures of protein complexes by molecular replacement with Phaser , 2006, Acta crystallographica. Section D, Biological crystallography.

[25]  Kevin Cowtan,et al.  research papers Acta Crystallographica Section D Biological , 2005 .

[26]  K. Campbell,et al.  Identification of alpha-dystroglycan as a receptor for lymphocytic choriomeningitis virus and Lassa fever virus. , 1998, Science.

[27]  Z. Otwinowski,et al.  Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.

[28]  Z. Otwinowski,et al.  [20] Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.